CPI and Quotient Sciences have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies. The JV will combine Quotient Sciences’ Translational Pharmaceutics® platform with CPI’s expertise in small-scale manufacture of RNA and LNP encapsulation to deliver a first-of-its-kind, integrated offering for the development of mRNA drug products. The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence.

CPI, Quotient Sciences to Accelerate RNA Therapies with Joint… | CPI